Theravance Biopharma, Inc. Remaining Share Repurchase Authorization
Theravance Biopharma, Inc. (TBPH) had Remaining Share Repurchase Authorization of $30.40 million as of 2023-09-30, per its 10-Q filed 2023-11-09.
Discontinued › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 · last filed 2023-11-09
- 2023-09-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $30.40M.
- 2023-06-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $61.20M.
- 2023-03-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $141.70M.
| Period end | Stock Repurchase Program, Remaining Authorized Repurchase Amount |
|---|---|
| 2023-09-30 | $30.40M 10-Q · filed 2023-11-09 |
| 2023-06-30 | $61.20M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $141.70M 10-Q · filed 2023-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |